Chemed Dividendi e riacquisti
Criteri Dividendo verificati 0/6
Chemed è una società che paga dividendi con un rendimento attuale di 0.48%.
Informazioni chiave
0.5%
Rendimento del dividendo
9.8%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | 10.3% |
| Rendimento futuro dei dividendi | 0.5% |
| Crescita dei dividendi | 8.0% |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | 12% |
Aggiornamenti recenti su dividendi e riacquisti
Recent updates
Aggiornamento narrativa • Aug 27
CHE: Buybacks Activism And Dividend Growth Will Shape Measured Returns
Analysts have raised their price target on Chemed from $501.50 to $552.00, citing updated assumptions around revenue growth, profit margins and a slightly higher forward P/E multiple. What’s in the News for Chemed Chemed declared a quarterly cash dividend of US$0.70 per share, payable on September 3, 2026, to shareholders of record on August 17, 2026.
Aggiornamento narrativa • Aug 13
CHE: Dividend Growth And Activist Pressure Will Shape Balanced Return Outlook
Analysts have raised their price target for Chemed from $500 to $590, reflecting updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What’s in the News for Chemed Chemed declared a quarterly cash dividend of US$0.70 per share, payable on September 3, 2026, to shareholders of record as of August 17, 2026.Seeking Alpha • Aug 05
Chemed Corporation: Why A Spin-Off Could Unlock Its Hidden Value
Summary Chemed Corporation (CHE) receives a Buy rating with a $632/share target, driven by activist pressure for a spin-off to eliminate the conglomerate discount. VITAS has successfully reengineered its patient mix, sharply reducing Medicare Cap penalties and driving 8.8% revenue growth and 18.2% Adjusted EBITDA margin in Q2. Roto-Rooter faces structural margin pressure from rising digital marketing costs, but B2B expansion and operational efficiencies are expected to support future growth. Barington Capital’s activist involvement is a key catalyst, with a spin-off potentially unlocking an 18% upside by repricing both segments at fair multiples. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 29
CHE: Buybacks And Activist Pressure Will Shape Margins And Measured Returns
Analysts have lifted their price target fair value for Chemed from $474 to $501.50, citing updated assumptions on revenue growth, profit margins and future P/E that result in a higher overall valuation. What’s in the News for Chemed From April 1, 2026 to June 30, 2026, Chemed repurchased 210,000 shares for US$89.8 million, representing 1.59% of its shares, and has now completed the repurchase of 12,570,646 shares for US$2.91b under the buyback first announced on February 22, 2011.Aggiornamento narrativa • Jul 13
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.Aggiornamento narrativa • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.Aggiornamento narrativa • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Aggiornamento narrativa • Jun 01
CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Aggiornamento narrativa • Apr 27
CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).Aggiornamento narrativa • Apr 10
CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.Aggiornamento narrativa • Mar 27
CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).Aggiornamento narrativa • Mar 10
CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).Nuova narrativa • Feb 27
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Feb 24
CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).Aggiornamento narrativa • Feb 10
CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.Aggiornamento narrativa • Jan 23
CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Articolo di analisi • Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Articolo di analisi • Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Articolo di analisi • Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Aggiornamento narrativa • Sep 03
New Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: CHE non sta pagando un dividendo degno di nota per il mercato US, pertanto non è necessario verificare se i pagamenti sono stabili.
Dividendo in crescita: CHE non sta pagando un dividendo degno di nota per il mercato US, pertanto non è necessario verificare se i pagamenti stanno aumentando.
Rendimento dei dividendi rispetto al mercato
| Chemed Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (CHE) | 0.5% |
| Fondo del 25% del mercato (US) | 1.4% |
| Top 25% del mercato (US) | 4.2% |
| Media del settore (Healthcare) | 2.0% |
| Analista previsionale (CHE) (fino a 3 anni) | 0.5% |
Dividendo notevole: Il dividendo di CHE ( 0.48% ) non è degno di nota rispetto al 25% inferiore dei pagatori di dividendi nel mercato US ( 1.38% ).
Dividendo elevato: Il dividendo di CHE ( 0.48% ) è basso rispetto al 25% dei maggiori pagatori di dividendi nel mercato US ( 4.18%.
Distribuzione degli utili agli azionisti
Copertura degli utili: CHE non sta pagando un dividendo degno di nota per il mercato US.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: CHE non sta pagando un dividendo degno di nota per il mercato US.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/20 13:25 |
| Prezzo dell'azione a fine giornata | 2026/09/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Chemed Corporation è coperta da 10 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |